TY - JOUR
T1 - International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid*
AU - the EADV Autoimmune Bullous Skin Disease Task Force
AU - Masmoudi, W.
AU - Vaillant, M.
AU - Vassileva, S.
AU - Patsatsi, A.
AU - Quereux, G.
AU - Moltrasio, C.
AU - Abasq, C.
AU - Prost-Squarcioni, C.
AU - Kottler, D.
AU - Kiritsi, D.
AU - Litrowski, N.
AU - Plantin, P.
AU - Friedrichsen, L.
AU - Zebrowska, A.
AU - Duvert-Lehembre, S.
AU - Hofmann, S.
AU - Ferranti, V.
AU - Jouen, F.
AU - Joly, P.
AU - Hebert, V.
N1 - Funding Information:
We are grateful to Nikki Sabourin-Gibbs, Rouen University Hospital, for writing assistance and review of the manuscript in English. We are grateful to Sarah Bastos, Joost Meijer, Saskia Ingen-Housz-Oro, Christophe Bedane, Sebastien Debarbieux, Hana Jedlickova, Guillaume Chaby, Michel D?Incan, Claudio Feliciani, Claire Boulard, Aude Roussel, Marie Aleth Richard and Jeremy Gottlieb for their collaboration and inclusion of patients.
Publisher Copyright:
© 2020 British Association of Dermatologists
PY - 2021/6
Y1 - 2021/6
N2 - Background: The Bullous Pemphigoid Disease Area Index (BPDAI) score has been proposed to provide an objective measure of bullous pemphigoid (BP) activity. Objectives: The objective of this study was to calculate BPDAI cut-off values defining mild, moderate and severe BP. We also aimed to assess the interrater reliability and correlation with the number of daily new blisters, and anti-BP180 and anti-BP230 antibodies. Methods: Severity scores were recorded by two blinded investigators. Anti-BP180 and anti-BP230 antibodies were measured using an enzyme-linked immunosorbent assay (ELISA). Cut-off values defining mild, moderate and severe subgroups were calculated based on the 25th and 75th percentiles of the BPDAI score. Results: In total, 285 patients with BP were enrolled from 50 dermatology departments in Europe. Median BPDAI activity was 37·5 points (range 0–164). Cut-off values corresponding to the first and third quartiles of the BPDAI score were 20 and 57, respectively; thus, these values were used to define mild (≤ 19), moderate (≥ 20 and ≤ 56) and severe (≥ 57) BP. The median BPDAI score for patients with ≤ 10 daily new blisters was 26 [interquartile range (IQR) 17–45], and for patients with > 10 daily new blisters the median score was 55 (IQR 39–82). The BPDAI intraclass correlation coefficient measured at baseline was 0·97 and remained higher than 0·90 up to month 6. The improvement in the BPDAI score was correlated with the absolute decrease in anti-BP180 ELISA value (Spearman’s rank r = 0·34, P < 0·004), but not with anti-BP230 antibodies (r = 0·17, P = 0·15). Conclusions: This study suggests cut-off values of 20–57 for BPDAI to distinguish mild, moderate and severe BP, and confirms that it is a robust tool to assess BP severity precisely.
AB - Background: The Bullous Pemphigoid Disease Area Index (BPDAI) score has been proposed to provide an objective measure of bullous pemphigoid (BP) activity. Objectives: The objective of this study was to calculate BPDAI cut-off values defining mild, moderate and severe BP. We also aimed to assess the interrater reliability and correlation with the number of daily new blisters, and anti-BP180 and anti-BP230 antibodies. Methods: Severity scores were recorded by two blinded investigators. Anti-BP180 and anti-BP230 antibodies were measured using an enzyme-linked immunosorbent assay (ELISA). Cut-off values defining mild, moderate and severe subgroups were calculated based on the 25th and 75th percentiles of the BPDAI score. Results: In total, 285 patients with BP were enrolled from 50 dermatology departments in Europe. Median BPDAI activity was 37·5 points (range 0–164). Cut-off values corresponding to the first and third quartiles of the BPDAI score were 20 and 57, respectively; thus, these values were used to define mild (≤ 19), moderate (≥ 20 and ≤ 56) and severe (≥ 57) BP. The median BPDAI score for patients with ≤ 10 daily new blisters was 26 [interquartile range (IQR) 17–45], and for patients with > 10 daily new blisters the median score was 55 (IQR 39–82). The BPDAI intraclass correlation coefficient measured at baseline was 0·97 and remained higher than 0·90 up to month 6. The improvement in the BPDAI score was correlated with the absolute decrease in anti-BP180 ELISA value (Spearman’s rank r = 0·34, P < 0·004), but not with anti-BP230 antibodies (r = 0·17, P = 0·15). Conclusions: This study suggests cut-off values of 20–57 for BPDAI to distinguish mild, moderate and severe BP, and confirms that it is a robust tool to assess BP severity precisely.
UR - http://www.scopus.com/inward/record.url?scp=85096862128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096862128&partnerID=8YFLogxK
U2 - 10.1111/bjd.19611
DO - 10.1111/bjd.19611
M3 - Article
C2 - 33067805
AN - SCOPUS:85096862128
SN - 0007-0963
VL - 184
SP - 1106
EP - 1112
JO - British Journal of Dermatology
JF - British Journal of Dermatology
IS - 6
ER -